The Ohio State University College of Medicine, Columbus, Ohio, USA
J Med Ethics. 2023 Feb;49(2):115-120. doi: 10.1136/medethics-2021-107892. Epub 2022 Feb 10.
Since the publication of the successful animal trials of the Biobag, a prototypical extrauterine support for extremely premature neonates, numerous ethicists have debated the potential implications of such a device. Some have argued that the Biobag represents a natural evolution of traditional newborn intensive care, while others believe that the Biobag would create a new class of being for the patients housed within. Kingma and Finn argued in for making a categorical distinction between fetuses, newborns and 'gestatelings' in a Biobag on the basis of a conceptual distinction between ectogenesis versus ectogestation. Applying their arguments to the clinical realities of newborn intensive care, however, demonstrates the inapplicability of their ideas to the practice of medicine. Here, I present three clinical examples of the difficulty and confusion their argument would create for clinicians and offer a possible remedy: namely, discarding the term 'artificial womb' in favour of 'Biobag'.
自成功进行了将 Biobag(一种为极早产儿提供的子宫外支持的原型设备)用于动物试验以来,众多伦理学家一直在争论这种设备可能带来的影响。一些人认为,Biobag 代表了传统新生儿重症监护的自然发展,而另一些人则认为,Biobag 将为其中收容的患者创造出一种新的存在类别。Kingma 和 Finn 在 中主张,基于胚胎外发生与胚胎外孕育之间的概念区别,在 Biobag 中对胎儿、新生儿和“gestatelings”进行分类,然而,将他们的论点应用于新生儿重症监护的临床现实表明,他们的观点不适用于医学实践。在这里,我提出了三个临床实例,说明他们的论点会给临床医生带来的困难和困惑,并提供了一种可能的解决方案:即用“Biobag”取代“人工子宫”一词。